2020
DOI: 10.1073/pnas.2004168117
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 . In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the im… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

59
2,023
3
71

Year Published

2020
2020
2021
2021

Publication Types

Select...
8
1
1

Relationship

2
8

Authors

Journals

citations
Cited by 1,785 publications
(2,156 citation statements)
references
References 27 publications
59
2,023
3
71
Order By: Relevance
“…Overall, we have described an easily accessible assay to study neutralizing antibody responses to SARS-CoV-2 in a biosafety-level-2 laboratory. This assay allows human sera or plasma samples to be screened in a convenient 96-well format, which will help facilitate the testing of large numbers of patient samples to better understand the development of immunity and to potentially screen donors for passive transfer of convalescent plasma [25,55].…”
Section: Discussionmentioning
confidence: 99%
“…Overall, we have described an easily accessible assay to study neutralizing antibody responses to SARS-CoV-2 in a biosafety-level-2 laboratory. This assay allows human sera or plasma samples to be screened in a convenient 96-well format, which will help facilitate the testing of large numbers of patient samples to better understand the development of immunity and to potentially screen donors for passive transfer of convalescent plasma [25,55].…”
Section: Discussionmentioning
confidence: 99%
“…The authors cautioned that the variability of neutralising antibody development may raise a concern about their role on disease progression. Nonetheless, the use of convalescent plasma has been encouraged and reported recently in a prospective study of 10 patients with severe COVID-19 [28]. In this uncontrolled trial, the administration of plasma containing high titres of SARS-CoV-2 neutralising antibodies was shown to be effective on several clinical, biochemical and radiological parameters, in parallel with a prompt viral suppression.…”
Section: Is There a Role For Ade In Covid-19?mentioning
confidence: 99%
“…Indeed, for other coronaviruses, neutralizing antibodies are protective in mouse models of infection [16][17][18][19][20] and associated with at least some reduced susceptibility to re-infection or disease in humans [15,21,22]. Furthermore, anecdotal reports suggest that passive transfer of neutralizing antibodies to sick patients may help alleviate disease from SARS-CoV-2 and its close relative SARS-CoV [23][24][25].…”
Section: Introductionmentioning
confidence: 99%